Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment

Molecular Psychiatry

Volumn 20, Issue 10, 2015, Pages 1179-1187

  Brendel, M ^a   Jaworska, A ^b,c   Herms, J ^b,d   Trambauer, J ^a   Rotzer C ^a   Gildehaus, F J ^a   Carlsen, J ^a   Cumming, P ^e   Bylund, J ^f   Luebbers, T ^f   Bartenstein, P ^a,d   Steiner, H ^a,b   Haass, C ^a,b,d   Baumann, K ^f   Rominger, A ^a,d  

^a UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^d Germany 3 Munich Cluster for Systems Neurology   (Germany)

^e UNIVERSITY OF OSLO   (Norway)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; FLORBETABEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; UNCLASSIFIED DRUG; [8 (4 FLUOROPHENYL)[1,2,4]TRIAZOLO[1,5 A]PYRIDIN 2 YL][1 (3METHYL [1,2,4]THIADIAZOL 5 YL)PIPERIDIN 4 YL]AMINE; 4-(N-METHYLAMINO)-4'-(2-(2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)STILBENE; AMYLOID PRECURSOR PROTEIN; ANILINE DERIVATIVE; SECRETASE; STILBENE DERIVATIVE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; CEREBELLUM; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HEK293 CELL LINE; HISTOGRAM; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUSE MODEL; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CASE CONTROL STUDY; CEREBRAL AMYLOID ANGIOPATHY; DIAGNOSTIC IMAGING; DISEASE MODEL; ENZYMOLOGY; LONGITUDINAL STUDY; METABOLISM; PATHOLOGY; PLAQUE, AMYLOID; PROCEDURES; SYNTHESIS; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANILINE COMPOUNDS; ANIMALS; CASE-CONTROL STUDIES; CEREBRAL AMYLOID ANGIOPATHY; DISEASE MODELS, ANIMAL; FEMALE; LONGITUDINAL STUDIES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; STILBENES;

EID: 84942549558     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.74     Document Type: Article

References (44)

1. Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM. Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement 2008; 4: 316-323.
2. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
3. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-112.
4. Sun X, Jin L, Ling P. Review of drugs for Alzheimer's disease. Drug Discov Ther 2012; 6: 285-290.
5. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-1341.
6. Herrmann N, Li A, Lanctot K. Memantine in dementia: a review of the current evidence. Exp Opin Pharmacother 2011; 12: 787-800.
7. Dhillon S. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type. Drugs 2011; 71: 1209-1231.
8. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T et al. Chronic treatment with the gamma-secretase inhibitor LY-411, 575 inhibits beta-Amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279: 12876-12882.
9. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013; 369: 341-350.
10. De Strooper B. Lessons from a failed gamma-secretase Alzheimer trial. Cell 2014; 159: 721-726.
11. Bittner T, Fuhrmann M, Burgold S, Jung CK, Volbracht C, Steiner H et al. Gammasecretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J Neurosci 2009; 29: 10405-10409.
12. Blennow K, Zetterberg H, Haass C, Finucane T. Semagacestat's fall: where next for AD therapies? Nat Med 2013; 19: 1214-1215.
13. Liebscher S, Page RM, Kafer K, Winkler E, Quinn K, Goldbach E et al. Chronic gamma-secretase inhibition reduces amyloid plaque-Associated instability of preand postsynaptic structures. Mol Psychiatry 2014; 19: 937-946.
14. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10: 698-712.
15. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212-216.
16. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 2003; 278: 30748-30754.
17. Ebke A, Luebbers T, Fukumori A, Shirotani K, Haass C, Baumann K et al. Novel gamma-secretase enzyme modulators directly target presenilin protein. J Biol Chem 2011; 286: 37181-37186.
18. Jumpertz T, Rennhack A, Ness J, Baches S, Pietrzik CU, Bulic B et al. Presenilin is the molecular target of acidic gamma-secretase modulators in living cells. PLoS One 2012; 7: e30484.
19. Ohki Y, Higo T, Uemura K, Shimada N, Osawa S, Berezovska O et al. Phenylpiperidine-type gamma-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J 2011; 30: 4815-4824.
20. Pozdnyakov N, Murrey HE, Crump CJ, Pettersson M, Ballard TE, Am Ende CW et al. gamma-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. J Biol Chem 2013; 288: 9710-9720.
21. Imbimbo BP, Del Giudice E, Colavito D, D'Arrigo A, Dalle Carbonare M, Villetti G et al. 1-(3', 4'-Dichloro-2-fluoro[1, 1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-Amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther 2007; 323: 822-830.
22. Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X et al. Modulation of gamma-secretase reduces beta-Amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 2010; 67: 769-780.
23. Sivilia S, Lorenzini L, Giuliani A, Gusciglio M, Fernandez M, Baldassarro VA et al. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neurosci 2013; 14: 44.
24. Rogers K, Felsenstein KM, Hrdlicka L, Tu Z, Albayya F, Lee W et al. Modulation of gamma-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Mol Neurodegener 2012; 7: 61.
25. Van Broeck B, Chen JM, Treton G, Desmidt M, Hopf C, Ramsden N et al. Chronic treatment with a novel gamma-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. Br J Pharmacol 2011; 163: 375-389.
26. Manook A, Yousefi BH, Willuweit A, Platzer S, Reder S, Voss A et al. Small-Animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One 2012; 7: e31310.
27. Rominger A, Brendel M, Burgold S, Keppler K, Baumann K, Xiong G et al. Longitudinal assessment of cerebral beta-Amyloid deposition in mice overexpressing Swedish mutant beta-Amyloid precursor protein using 18F-florbetaben PET. J Nucl Med 2013; 54: 1127-1134.
28. Snellman A, Lopez-Picon FR, Rokka J, Salmona M, Forloni G, Scheinin M et al. Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med 2013; 54: 1434-1441.
29. Teipel SJ, Buchert R, Thome J, Hampel H, Pahnke J. Development of Alzheimerdisease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Prog Neurobiol 2011; 95: 547-556.
30. Baumann K, Flohr A, Goetschi E, Green L, Jolidon S, Knust H et al. Preparation of heteroaryl substituted piperidines as-Amyloid modulators. US 20110201605 A1. 2011.
31. Kretner B, Fukumori A, Gutsmiedl A, Page RM, Luebbers T, Galley G et al. Attenuated Abeta42 responses to low potency gamma-secretase modulators can be overcome for many pathogenic presenilin mutants by second-generation compounds. J Biol Chem 2011; 286: 15240-15251.
32. Brockhaus M, Grunberg J, Rohrig S, Loetscher H, Wittenburg N, Baumeister R et al. Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling. Neuroreport 1998; 9: 1481-1486.
33. Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JN, Bohrmann B et al. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci 2003; 23: 8989-9003.
34. Page RM, Baumann K, Tomioka M, Perez-Revuelta BI, Fukumori A, Jacobsen H et al. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-Associated presenilin mutations and gamma-secretase modulation. J Biol Chem 2008; 283: 677-683.
35. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 2002; 61: 797-805.
36. Hahn S, Bruning T, Ness J, Czirr E, Baches S, Gijsen H et al. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to gamma-secretase modulators regardless of their potency and structure. J Neurochem 2011; 116: 385-395.
37. Teipel SJ, Buchert R, Thome J, Hampel H, Pahnke J. Development of Alzheimerdisease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Prog Neurobiol 2011; 95: 547-556.
38. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW et al. Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 2012; 69: 1430-1440.
39. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008; 65: 1031-1038.
40. Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L. gamma-Secretase inhibitors and modulators. Biochim Biophys Acta 2013; 1828: 2898-2907.
41. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009; 302: 2557-2564.
42. Yu Y, Logovinsky V, Schuck E, Kaplow J, Chang MK, Miyagawa T et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel gammasecretase modulator, E2212, in healthy human subjects. J Clin Pharmacol 2014; 54: 528-536.
43. Younkin SG. The role of A beta 42 in Alzheimer's disease. J Physiol Paris 1998; 92: 289-292.
44. Martin-Moreno AM, Brera B, Spuch C, Carro E, Garcia-Garcia L, Delgado M et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-Amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 2012; 9: 8.